Latest Breaking News On - Product development medical affairs - Page 1 : comparemela.com

Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024

– Cabozantinib in combination with atezolizumab reduced the risk of disease progression or death by 35% in patients with metastatic castration-resistant prostate cancer – – Findings to be.

United statesNeeraj agarwalAmy petersonAmerican cancer societyEuropean unionUniversity of utahExchange commissionProduct development medical affairsTakeda pharmaceutical company limitedClinical research at huntsman cancer instituteExelixis incDrug administrationAmerican society of clinical oncologyOral abstract sessionProstate cancerAmerican society

Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer

– STELLAR-305 is Exelixis’ first pivotal study in squamous cell carcinoma of the head and neck – – Trial will evaluate the potential of inhibition of VEGF, MET and AXL, which are elevated.

Amy petersonProduct development medical affairsRadiology committeeExelixis incExchange commissionExecutive vice presidentProduct developmentMedical affairsChief medical officerResponse evaluation criteriaSolid tumorsBlinded independent radiology committeeHypertensive crisisPlantar erythrodysesthesiaImpaired wound healingPosterior leukoencephalopathy syndrome

Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma

– Phase 1b/2 clinical trial expected to begin enrolling patients before year-end 2023 – .

United statesAmy petersonDimitry sa nuytenProduct development medical affairsExelixis incAmerican cancer societyExchange commissionArcus biosciencesExecutive vice presidentProduct developmentMedical affairsChief medical officerArcus bioscienceAnnual reportQuarterly reportsPrivate securities litigation reform act

Exelixis (EXEL) Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023

Exelixis (EXEL) Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSumanta palAmy petersonDatabase consortiumInternational kidney cancer symposiumProduct development medical affairsExelixis incInternational metastaticCity of hope comprehensive cancer centerOral abstractsKidney cancer symposiumClinical professorHope comprehensive cancer centerExecutive vice presidentProduct developmentMedical affairs

Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023

– Results for Exelixis’ next-generation tyrosine kinase inhibitor demonstrated an objective response rate of 38% and a disease control rate of 88% – – Anti-tumor activity was observed in.

United statesSumanta palAmy petersonCity of hope comprehensive cancer centerInternational metastaticInternational kidney cancer symposiumProduct development medical affairsEuropean unionAmerican cancer societyDatabase consortiumExchange commissionExelixis incOral abstractsKidney cancer symposiumClinical professorHope comprehensive cancer center